Itraconazol Arena (Itraconazole)

Itraconazole is employed to manage fungal diseases that affect various organ systems and skin layers.

• Aspergillosis: controls invasive pulmonary infection and reduces fungal burden.
• Candidiasis: treats systemic candidemia and deep‑tissue candidal infections.
• Blastomycosis: eradicates Blastomyces dermatitidis infection in lungs and disseminated sites.
• Histoplasmosis: resolves Histoplasma capsulatum infection, especially in immunocompromised patients.
• Dermatophytosis: clears superficial skin infections caused by dermatophytes.

• Itraconazole inhibits the fungal cytochrome P450 enzyme lanosterol 14α‑demethylase, a key step in ergosterol synthesis. By blocking ergosterol production, the drug disrupts fungal cell membrane integrity, leading to impaired growth and eventual cell death. This mechanism targets a broad range of pathogenic fungi while sparing human cells that use cholesterol instead of ergosterol.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Vomiting: occasional emesis after dosing.
• Abdominal pain: discomfort or cramps in the gastrointestinal tract.
• Headache: transient mild to moderate headache.
• Rash: skin erythema or pruritus.
• Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects

• Hepatotoxicity: severe liver injury, jaundice, or hepatitis.
• Congestive heart failure: fluid retention and reduced cardiac output.
• Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement.
• Visual disturbances: blurred vision or photopsia.
• Arrhythmias: irregular heart rhythms, especially in patients with pre‑existing cardiac disease.
• Severe hypersensitivity: anaphylaxis or angioedema.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

• Liver function monitoring: check baseline transaminases and repeat periodically.
• Cardiac assessment: avoid in patients with existing heart failure or significant arrhythmias.
• Drug review: assess for concomitant medications that share CYP3A4 metabolism.
• Hypersensitivity check: discontinue if signs of allergic reaction appear.
• Pregnancy and lactation: use only if benefits outweigh potential risks.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Itraconazole interacts with several agents through CYP3A4 inhibition and other pathways.

Major Interactions (Avoid)

• Rifampin: strong CYP3A4 inducer that markedly reduces itraconazole exposure.
• St. John’s wort: herbal inducer leading to sub‑therapeutic levels.
• Certain anti‑arrhythmics (e.g., amiodarone): risk of serious cardiac toxicity.
• Protease inhibitors (e.g., ritonavir): may cause unpredictable plasma concentrations.
• Certain statins (e.g., simvastatin): increased risk of myopathy.

Moderate Interactions (Monitor Closely)

• Warfarin: enhanced anticoagulant effect, monitor INR.
• Oral contraceptives: reduced efficacy, consider alternative contraception.
• Macrolide antibiotics (e.g., erythromycin): may increase itraconazole levels.
• Benzodiazepines metabolized by CYP3A4: possible sedation enhancement.
• Digoxin: potential increase in serum concentration.